🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Innate Pharma S.A. (IPHA)
NASDAQ: IPHA · Real-Time Price · USD
0.9399
-0.0901 (-8.75%)
At close: Nov 19, 2026, 4:00 PM EST
0.9300
-0.0099 (-1.05%)
After-hours: Nov 19, 2026, 4:10 PM EST

Innate Pharma Stock Forecast

Stock Price Forecast

According to 3 analysts polled by S&P Global, Innate Pharma stock has a consensus rating of "Buy" and an average price target of $8.00. The average 1-year stock price forecast is 751.15% higher than the current stock price, while the lowest is $7.00 (+644.76%) and the highest is $9.00 (+857.55%).

Price Target: $8.00 (+751.15%)
Analyst Consensus: Buy

Price Target

Chart
TargetLowAverageMedianHigh
Price$7.00$8.00$8.00$9.00
Change+644.76%+751.15%+751.15%+857.55%

Analyst Ratings

The average analyst rating for Innate Pharma stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Chart
RatingMar '26Apr '26May '26Aug '26Sep '26Nov '26
Strong Buy333332
Buy000000
Hold111001
Sell000000
Strong Sell000000
Total444333

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
Leerink Partners
Leerink Partners
Hold
Downgrades
$1
HoldDowngrades$1+6.39%Nov 19, 2026
BTIG
BTIG
Buy
Maintains
$9
BuyMaintains$9+857.55%Nov 19, 2026
H.C. Wainwright
H.C. Wainwright
Buy
Maintains
$7
BuyMaintains$7+644.76%Nov 18, 2026

Financial Forecast

Revenue This Year
57.12M
from 9.01M
Increased by 534.36%
Revenue Next Year
90.00M
from 57.12M
Increased by 57.54%
EPS This Year
0.23
EPS Next Year
0.91
from 0.23
Increased by 293.48%
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
24.70M57.67M61.64M20.12M9.01M57.12M
Revenue Growth
-64.60%133.47%6.88%-67.36%-55.25%534.36%
Operating Income
-47.83M-16.43M-12.67M-51.58M-54.01M-3.67M
Net Income
-52.81M-58.10M-7.57M-49.47M-49.18M-1.28M
EPS
-----0.23
Forward PE
-----3.73
Free Cash Flow
-----52.90M20.07M
No. Analysts
-----4
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is EUR.

Revenue Forecast

Revenue202620272028
High84.3M
Avg57.1M
Low8.2M

Revenue Growth

Revenue Growth202620272028
High
836.1%
Avg
534.4%
Low
-9.0%

EPS Forecast

EPS202620272028
High0.23
Avg0.23
Low0.23

EPS Growth

EPS Growth202620272028
High-
Avg-
Low-